8-K 1 d45598e8vk.htm FORM 8-K e8vk
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 19, 2007 (April 13, 2007)
REPLIDYNE, INC.
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other jurisdiction of
incorporation or organization) 		  000-52082
(Commission File Number) 		  84-1568247
(I.R.S. Employer
Identification No.)
         
1450 Infinite Drive,
Louisville, Colorado
(Address of principal
executive offices) 		       
80027
(Zip Code)
303-996-5500
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

INFORMATION TO BE INCLUDED IN THE REPORT
Item 5.02   Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) Ralph E. Christoffersen, Ph.D., a member of the board of directors of the Company (the “Board”) whose term will expire at the Company’s 2007 annual stockholder meeting (the “Annual Meeting”), indicated to the Company on April 13, 2007 that he does not intend to stand for re-election at the Annual Meeting. Dr. Christoffersen’s decision not to stand for re-election is not due to any disagreement with the Company.
     Henry Wendt, a member of the Board whose term was to expire in 2008, indicated to the Company on April 13, 2007 that he has determined to retire from the Board effective as of the date of the Annual Meeting. Mr. Wendt’s resignation is due to retirement and not due to any disagreement with the Company.

 

 

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  REPLIDYNE, INC.
 		  
Dated: April 19, 2007  By:   /s/ Mark L. Smith    
    Mark L. Smith   
    Chief Financial Officer
Principal Accounting Officer